Chen, GuoYang, BaoqiZhang, ZhaoxiaYang, QingYan, XiaoxiaoMurrell, Dédée FZhang, Furen2020-01-022020-01-022018-07Chen Guo, Yang Baoqi, Zhang Zhaoxia, Yang Qing, Yan Xiaoxiao, Murrell Dédée F, Zhang Furen. Chinese version of the treatment of autoimmune bullous disease quality of life questionnaire: Reliability and validity. Indian Journal of Dermatology, Venereology and Leprology. 2018 Jul; 84(4): 431-4360378-63230973-3922http://imsear.searo.who.int/handle/123456789/192392Background: Treatments for autoimmune blistering disease carry significant risks of medical complications and can affect the patient's quality of life. Recently, the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire was developed in Australia. Objective: The objective of this study was to evaluate the reliability and validity of the Chinese version of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire in Chinese patients with autoimmune blistering diseases. Methods: The Chinese version of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire was produced by forward-backward translation and cross-cultural adaptation of the original English version. Autoimmune blistering disease patients recruited in the study self-administered the Chinese Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, the Dermatology Life Quality Index and the 36-item Short-Form Health Survey. Reliability of the Chinese Treatment of Autoimmune Bullous Disease Quality of Life was evaluated using internal consistency and test-retest (days 0 and 7) methods. Validity was analyzed by face, content, construct, convergent and discriminant validity measures. Results: A total of 86 autoimmune blistering disease patients were recruited for the study. Cronbach's alpha coefficient was 0.883 and the intraclass correlation coefficient was 0.871. Face and content validities were satisfactory. Convergent validity testing revealed correlation coefficients of 0.664 for the Treatment of Autoimmune Bullous Disease Quality of Life and Dermatology Life Quality Index and –0.577 for the Treatment of Autoimmune Bullous Disease Quality of Life and 36-item Short-Form Health Survey. With respect to discriminant validity, no significant differences were observed in the Treatment of Autoimmune Bullous Disease Quality of Life scores of men and women (t = 0.251, P = 0.802), inpatients and outpatients (t = 0.447, P = 0.656), patients on steroids and steroid-sparing medications (t = 0.672, P = 0.503) and patients with different autoimmune blistering disease subtypes (F = 0.030, P = 0.971). Limitations: Illiterate patients were excluded from the study. The patients were from a single hospital and most of their conditions were in a relatively stable status. Conclusion: The Chinese version of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire is a reliable and valid instrument to measure treatment burden and to serve as an end point in clinical trials in Chinese autoimmune blistering disease patients.Autoimmune bullous diseasequality of lifereliability and validityChinese version of the treatment of autoimmune bullous disease quality of life questionnaire: Reliability and validityJournal ArticleIndiaDepartment of Dermatology, School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences; Department of Dermatology, Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences; Department of Dermatology, Shandong Provincial Hospital for Skin Diseases, Jinan; Department of Dermatology, Laiwu Institute of Dermatology, Laiwu, Shandong, ChinaDepartment of Dermatology, School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences; Department of Dermatology, Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences; Department of Dermatology, Shandong Provincial Hospital for Skin Diseases, Jinan, ChinaDepartment of Dermatology, Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences; Department of Dermatology, Shandong Provincial Hospital for Skin Diseases, Jinan, ChinaDepartment of Dermatology, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia